Megestrol Acetate for Fatigue Management in T-DXd Treated Breast Cancer

Exclusion Criteria

• •1. Severe underlying disease, comorbidities, active infection, or severe metabolic disorders
• •2. Clinically significant severe fatigue at baseline (FACIT-F score \<30)
• •3. Currently receiving other antitumor therapies
• •4. Pregnant or lactating patients
• •5. Poor compliance or unable to complete normal follow-up
• •6. History of allergy to megestrol acetate or other components of the formulation
• •7. History of thromboembolism (use with caution)
• •8. Other malignancies diagnosed within 5 years, except: resected non-melanoma skin cancer, adequately treated cervical carcinoma in situ, locally radically treated prostate cancer, surgically radically treated ductal carcinoma in situ, or malignancies diagnosed \>2 years ago with no current disease evidence and untreated for ≤2 years before randomization
• •9. Any condition judged by investigator that may affect study conduct or outcome assessment